Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Angely Loubert, Antoine Regnault, Juliette Meunier, Florian S Gutzwiller & Stéphane A Regnier. (2020) Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2103-2113.
Read now
Read now
Masakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, Osamu Hataji, Gary T Ferguson, Klaus F Rabe, Nobuya Hayashi, Hiroshi Okada, Mami Takikawa, Eric Bourne, Shaila Ballal, Kiernan DeAngelis, Magnus Aurivillius, Paul Dorinsky & Colin Reisner. (2019) Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2979-2991.
Read now
Read now
Jadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, Michael Humphries, Robert Fogel, Chau Thach, Francesco Patalano & Donald Banerji. (2017) Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 339-349.
Read now
Read now
Articles from other publishers (7)
Chihiro Kato, Hajime Yoshisue, Noriko Nakamura & Takayoshi Sasajima. (2022) Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance. Internal Medicine 61:6, pages 789-800.
Crossref
Crossref
Akira Koarai, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama & Hisatoshi Sugiura. (2022) Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. Respiratory Investigation 60:1, pages 90-98.
Crossref
Crossref
Satoru Inoue, Soniya Vaidya, Hanns-Christian Tillmann, Yohei Sakita, Surendra Machineni, Olivier Heudi & Kenichi Furihata. (2021) Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
David M. G. Halpin, Gerard J. Criner, Mark T. Dransfield, MeiLan K. Han, Benjamin Hartley, Catherine Harvey, C. Elaine Jones, Motokazu Kato, Peter Lange, Sally Lettis, David A. Lomas, Fernando J. Martinez, Neil Martin, Dave Singh, Robert Wise, Jinping Zheng & David A. Lipson. (2020) Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy 7:1, pages 101-118.
Crossref
Crossref
Melissa Lipari, Pramodini B. Kale-Pradhan & Sheila M. Wilhelm. (2020) Dual– Versus Mono–Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis. Annals of Pharmacotherapy 54:12, pages 1232-1242.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Crossref